Healthcare Industry News: BioMarin Pharmaceutical
News Release - March 6, 2007
TechniScan Medical Systems Taps Dr. John Klock for Board of DirectorsSALT LAKE CITY & SAN FRANCISCO--(HSMN NewsFeed)--John C. Klock, M.D., has joined the Board of Directors of TechniScan Medical Systems (TMS), Inc., a Salt Lake City-based developer of ultrasound technology for breast imaging. A board-certified Internist and Hematologist-Oncologist, Klock is the Chairman and Co-founder of Holistica Hawaii Preventive Medicine, where he is applying modern medical technologies for disease prediction and health screening to develop individualized programs for maintaining optimal health through prevention.
Dr. Klock has been integral in the start-up of five medical companies, holds eight granted U.S. patents and has been published more than 70 times in the most respected medical journals, ranging from the Western Journal of Medicine to the American Heart Journal to the New England Journal of Medicine. "John's long track record of successful medical ventures and research reputation serve as a tremendous validation of the potential of TechniScan's imaging technology," noted TechniScan President and CEO David C. Robinson.
In his capacity as a developer of biomedical companies over the course of the last 20 years, Klock was the Scientific Founder and Vice President of Glycomed, Inc. of Alameda, Calif.; Founder and President of Glyko, Inc. of Novata, Calif.; Founder and President of BioMarin Pharmaceutical Inc., also of Novata; and Chairman of Holistica Hawaii Preventive Medicine of Honolulu.
Prior to his research and work with these companies, Klock was Acting Director of the Cancer Research Institute at the University of California San Francisco, Acting Chief of Medical Oncology at San Francisco General Hospital and Scientific Director of the Institute of Cancer Research at Pacific Presbyterian Medical Center in San Francisco.
Klock received his B.S. from Louisiana State University and his M.D. from Tulane University. He completed his intern and residency work at the Children's Hospital and Adult Medical Center and University of California, both in San Francisco, and completed back-to-back post-doctoral fellowships in Hematology at UCSF and in Clinical Research in Oncology at the Harvard Medical School and Massachusetts General Hospital in Boston.
About TechniScan Medical Systems, Inc.
Founded in 1984, TMS (www.techniscanmedicalsystems.com) uses an ultrasound technology called inverse scattering, which makes use of the entire spectrum of information available from the ultrasound signal. The resulting diagnostic information includes ultrasound transmission tomography images in a format similar to that provided by MRI and CT imaging. In addition, UltraSound CT(TM) provides indices of speed and attenuation of sound, tissue properties that may provide physicians with valuable diagnostic information.
Source: TechniScan Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.